Quantitative Correlations between Radiosensitivity Biomarkers Show That the ATM Protein Kinase Is Strongly Involved in the Radiotoxicities Observed after Radiotherapy.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
09 Sep 2022
Historique:
received: 30 07 2022
revised: 05 09 2022
accepted: 07 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

Tissue overreactions (OR), whether called adverse effects, radiotoxicity, or radiosensitivity reactions, may occur during or after anti-cancer radiotherapy (RT). They represent a medical, economic, and societal issue and raise the question of individual response to radiation. To predict and prevent them are among the major tasks of radiobiologists. To this aim, radiobiologists have developed a number of predictive assays involving different cellular models and endpoints. To date, while no consensus has been reached to consider one assay as the best predictor of the OR occurrence and severity, radiation oncologists have proposed consensual scales to quantify OR in six different grades of severity, whatever the organ/tissue concerned and their early/late features. This is notably the case with the Common Terminology Criteria for Adverse Events (CTCAE). Few radiobiological studies have used the CTCAE scale as a clinical endpoint to evaluate the statistical robustness of the molecular and cellular predictive assays in the largest range of human radiosensitivity. Here, by using 200 untransformed skin fibroblast cell lines derived from RT-treated cancer patients eliciting OR in the six CTCAE grades range, correlations between CTCAE grades and the major molecular and cellular endpoints proposed to predict OR (namely, cell survival at 2 Gy (SF2), yields of micronuclei, recognized and unrepaired DSBs assessed by immunofluorescence with γH2AX and pATM markers) were examined. To our knowledge, this was the first time that the major radiosensitivity endpoints were compared together with the same cohort and irradiation conditions. Both SF2 and the maximal number of pATM foci reached after 2 Gy appear to be the best predictors of the OR, whatever the CTCAE grades range. All these major radiosensitivity endpoints are mathematically linked in a single mechanistic model of individual response to radiation in which the ATM kinase plays a major role.

Identifiants

pubmed: 36142346
pii: ijms231810434
doi: 10.3390/ijms231810434
pmc: PMC9498991
pii:
doi:

Substances chimiques

Biomarkers 0
Protein Kinases EC 2.7.-
ATM protein, human EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Commissariat Général à l'Investissement
ID : INDIRA project
Organisme : French National Cancer Institute
ID : PROUST project
Organisme : Centre National d'Études Spatiales
ID : ICARE project
Organisme : Région Auvergne Rhone-Alpes
ID : ERATOSTHENE project
Organisme : French-Lebanon partenariat Hubert Curien
ID : CEDRE 47880PE project
Organisme : Commissariat Général à l'Investissement
ID : INDIRA Project
Organisme : French National Cancer Institute
ID : PROUST project
Organisme : Centre National d'Études Spatiales
ID : ICARE project
Organisme : Région Auvergne Rhône-Alpes
ID : ERATOSTHENE Project
Organisme : the French-Lebanon partenariat Hubert Curien
ID : CEDRE 47880PE project,

Références

Int J Radiat Biol. 1997 Sep;72(3):271-83
pubmed: 9298107
Cancer Radiother. 2022 Sep;26(5):684-691
pubmed: 35227594
Clin Oncol (R Coll Radiol). 2007 Oct;19(8):614-5
pubmed: 17656077
Int J Radiat Biol. 1995 Oct;68(4):447-57
pubmed: 7594971
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Cancer Res. 1997 Oct 15;57(20):4600-7
pubmed: 9377575
Int J Radiat Biol Relat Stud Phys Chem Med. 1981 Apr;39(4):395-408
pubmed: 6971848
Mol Neurobiol. 2018 Jun;55(6):4973-4983
pubmed: 28786016
Ann ICRP. 2007;37(6):1-63
pubmed: 18762065
Mol Cell Biol. 2003 Aug;23(16):5706-15
pubmed: 12897142
Cancer Radiother. 2007 Nov;11(6-7):309-12
pubmed: 17962063
Int J Radiat Biol. 2020 Mar;96(3):394-410
pubmed: 31738647
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):353-360
pubmed: 29353653
EMBO J. 2003 Jun 2;22(11):2860-71
pubmed: 12773400
Am J Med Genet. 2002 Oct 30;115(3):125-9
pubmed: 12407692
Int J Radiat Biol. 2021;97(3):317-328
pubmed: 33320757
Ann ICRP. 2012 Feb;41(1-2):1-322
pubmed: 22925378
Cancer Res. 1980 Mar;40(3):926-32
pubmed: 7471106
Radiat Res. 1984 Jul;99(1):73-84
pubmed: 6739728
Mol Neurobiol. 2014 Jun;49(3):1200-11
pubmed: 24277524
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Mutat Res. 2000 Nov 20;455(1-2):81-95
pubmed: 11113469
Toxicology. 2003 Nov 15;193(1-2):125-35
pubmed: 14599772
Radiother Oncol. 2005 Aug;76(2):112-8
pubmed: 16026874
J Pain Symptom Manage. 2019 Jul;58(1):92-99.e1
pubmed: 30974233
Mutat Res Rev Mutat Res. 2016 Oct - Dec;770(Pt B):369-386
pubmed: 27919342
J Pediatr Hematol Oncol. 2010 Jan;32(1):e28-30
pubmed: 20051774
Int J Mol Sci. 2020 Feb 24;21(4):
pubmed: 32102335
Br J Cancer. 1994 Mar;69(3):457-62
pubmed: 8123473
Radiat Res. 1995 Oct;144(1):26-35
pubmed: 7568768
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):450-60
pubmed: 26867874
Mol Neurobiol. 2022 Jan;59(1):556-573
pubmed: 34727321
Radiother Oncol. 2014 May;111(2):178-85
pubmed: 24785509
Front Radiat Ther Oncol. 2006;39:96-101
pubmed: 16394673
Int J Mol Sci. 2022 Jan 29;23(3):
pubmed: 35163494
Int J Radiat Biol. 1999 Oct;75(10):1275-82
pubmed: 10549604
Cancer Res. 1995 Mar 15;55(6):1232-4
pubmed: 7882314
J Exp Med. 1956 May 1;103(5):653-66
pubmed: 13319584
Int J Mol Sci. 2021 Jul 02;22(13):
pubmed: 34281212
Lancet Oncol. 2012 Jan;13(1):65-77
pubmed: 22169268
Cent European J Urol. 2020;73(3):295-299
pubmed: 33133656
Nature. 1975 Dec 4;258(5534):427-9
pubmed: 1196376
J Theor Biol. 2016 Apr 7;394:93-101
pubmed: 26807808
Br J Cancer. 2008 Jun 3;98(11):1845-51
pubmed: 18493234
Cancer Res. 1989 Sep 1;49(17):4705-14
pubmed: 2758405
Radiat Res. 2002 Oct;158(4):486-92
pubmed: 12236816
Cancer Res. 2000 Jan 15;60(2):390-4
pubmed: 10667592
Int J Radiat Biol. 2016;92(3):117-31
pubmed: 26907628
Int J Radiat Oncol Biol Phys. 1981 May;7(5):621-9
pubmed: 7275727
Curr Eye Res. 2021 Apr;46(4):546-557
pubmed: 32862699
Med Pediatr Oncol. 1996 Dec;27(6):564-70
pubmed: 8888819
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):690-693
pubmed: 29893278
Radiat Res. 1987 Sep;111(3):385-405
pubmed: 3659275
Br J Radiol. 1990 Aug;63(752):624-8
pubmed: 2400879
Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):251-66
pubmed: 12118559
Cancers (Basel). 2019 Jun 28;11(7):
pubmed: 31261657
Cancer Radiother. 2022 Aug 11;:
pubmed: 35965243
Br J Cancer. 1995 Feb;71(2):311-6
pubmed: 7841046
Semin Radiat Oncol. 2017 Oct;27(4):310-315
pubmed: 28865513
Int J Radiat Biol. 2008 Feb;84(2):107-25
pubmed: 18246480
Mutat Res. 1998 Aug 3;404(1-2):55-65
pubmed: 9729276
Oncogene. 2007 Dec 10;26(56):7717-9
pubmed: 18066083
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1357-1366
pubmed: 27325482
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1065-75
pubmed: 8985028
Cancer Res. 2004 Jan 15;64(2):500-8
pubmed: 14744762
Radiat Res. 2013 Aug;180(2):138-48
pubmed: 23886340
Int J Mol Sci. 2019 Oct 26;20(21):
pubmed: 31717816
Br J Cancer. 1998 Feb;77(4):614-20
pubmed: 9484819
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62
pubmed: 12679524
Int J Radiat Biol. 1988 Dec;54(6):911-28
pubmed: 2903889
Int J Radiat Biol. 2020 Mar;96(3):297-323
pubmed: 31852363
Bioessays. 1991 Dec;13(12):641-8
pubmed: 1789781
Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):301-309
pubmed: 35675851
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):667-74
pubmed: 25892583
Z Med Phys. 2004;14(1):7-16
pubmed: 15104005
Cancer. 2011 Apr 1;117(7):1429-37
pubmed: 21425143
J Biol Chem. 1998 Mar 6;273(10):5858-68
pubmed: 9488723
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1096-103
pubmed: 20605362
Radiat Res. 1987 Sep;111(3):406-23
pubmed: 3659276
J Biol Chem. 2001 Nov 9;276(45):42462-7
pubmed: 11571274
Nucleic Acids Res. 2008 Oct;36(17):5678-94
pubmed: 18772227
Lancet Oncol. 2003 Sep;4(9):529-36
pubmed: 12965273

Auteurs

Eymeric Le Reun (E)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Larry Bodgi (L)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.
Department of Radiation Oncology, American University of Beirut Medical Center, Riad El-Solh, Beirut 1107-2020, Lebanon.
Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Bliss Street, 11-0236 Riad El-Solh, Beirut 1107-2020, Lebanon.

Adeline Granzotto (A)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Laurène Sonzogni (L)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Mélanie L Ferlazzo (ML)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Joëlle Al-Choboq (J)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Laura El-Nachef (L)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Juliette Restier-Verlet (J)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Elise Berthel (E)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Clément Devic (C)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Audrey Bouchet (A)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Michel Bourguignon (M)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.
Department of Biophysics and Nuclear Medicine, Université Paris Saclay Versailles St. Quentin en Yvelines, 78035 Versailles, France.

Nicolas Foray (N)

Inserm, U1296 Unit, «Radiation: Defense, Health and Environment», Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH